Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Research

Prediabetes and Short-Term Outcomes in Nondiabetic Patients after Acute ST-Elevation Myocardial Infarction

Tian L. · Zhu J. · Liu L. · Liang Y. · Li J. · Yang Y.

Author affiliations

State Key Laboratory of Cardiovascular Disease and Cardiovascular Department, Emergency and Critical Care Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Related Articles for ""

Cardiology 2014;127:55-61

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: May 02, 2013
Accepted: July 25, 2013
Published online: November 13, 2013
Issue release date: December 2013

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

Objectives: A prediabetic state is defined as the time period before the development of symptomatic diabetes. Limited evidence is available for evaluating the correlation between prediabetes and short-term outcomes in nondiabetic patients with ST-elevation of myocardial infarction (STEMI). Methods: 4,787 nondiabetic patients with a diagnosis of STEMI based on typical onset of chest pain within 12 h were enrolled. Patients were followed up for 7 and 30 days after hospital admission. According to the 2013 Standards of Medical Care in Diabetes, the study population was stratified into three groups: normal, prediabetic and newly diagnosed diabetic patients. The primary outcomes of our study were all-cause mortality and major adverse cardiac events (MACE) on days 7 day and 30. Results: The proportions of patients with prediabetes and newly diagnosed diabetes were 31.1 and 19.2%, respectively. Rates of 7- and 30-day mortality and MACE were similar among the different HbA1c groups. Multivariable Cox regression analysis showed that compared with normal glucose metabolism, prediabetes (hazard ratio, HR, 1.003; 95% CI, 0.865-1.165) and newly diagnosed diabetes (HR, 0.887; 95% CI, 0.739-1.064) were not correlated with 30-day MACE. However, admission glucose was an independent predictor of short-term MACE (HR, 1.031; 95% CI, 1.017-1.046). Conclusions: In nondiabetic patients after STEMI, the incidence of latent diabetes mellitus was increased. Newly diagnosed diabetes and prediabetes were not correlated with short-term outcome in nondiabetic patients with STEMI, yet admission glucose level was an independent predictor of short-term MACE. To reduce the incidence of short-term MACE after STEMI, more attention should be paid to the control of increased glucose levels and intrinsic stress states.

© 2013 S. Karger AG, Basel


References

  1. Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(suppl 1):S11-S66.
  2. Sentell TL, He G, Gregg EW, Schillinger D: Racial/ethnic variation in prevalence estimates for United States prediabetes under alternative 2010 American Diabetes Association criteria: 1988-2008. Ethn Dis 2012;22:451-458.
    External Resources
  3. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222.
  4. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811.
  5. Santos-Oliveira R, Purdy C, da Silva MP, dos Anjos Carneiro-Leao AM, Machado M, Einarson TR: Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia 2011;54:1327-1334.
  6. Kadri Z, Danchin N, Vaur L, Cottin Y, Gueret P, Zeller M, Lablanche JM, Blanchard D, Hanania G, Genes N, Cambou JP, Investigators U: Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study. Heart 2006;92:910-915.
  7. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513.
  8. Hadjadj S, Coisne D, Mauco G, Ragot S, Duengler F, Sosner P, Torremocha F, Herpin D, Marechaud R: Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabet Med 2004;21:305-310.
  9. Ergelen M, Uyarel H, Cicek G, Isik T, Osmonov D, Gunaydin ZY, Bozbay M, Turer A, Gul M, Abanonu GB, Ilhan E: Which is worst in patients undergoing primary angioplasty for acute myocardial infarction? Hyperglycaemia? Diabetes mellitus? Or both? Acta Cardiol 2010;65:415-423.
  10. Ackermann RT, Cheng YJ, Williamson DF, Gregg EW: Identifying adults at high risk for diabetes and cardiovascular disease using hemoglobin A1c National Health and Nutrition Examination Survey 2005-2006. Am J Prev Med 2011;40:11-17.
  11. Lazzeri C, Valente S, Chiostri M, Picariello C, Attana P, Gensini GF: Glycated hemoglobin in ST-elevation myocardial infarction without previously known diabetes: its short and long term prognostic role. Diabet Res Clin Prac 2012;95:e14-e16.
  12. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial. Circulation 2004;110:1572-1578.
  13. Sen K, Mukherjee AK, Dharchowdhury L, Chatterjee A: A study to find out the proportion of prediabetes in patients with acute coronary syndrome in a medical college of Kolkata. J Indian Med Assoc 2008;106:776-778.
    External Resources
  14. Otten R, Kline-Rogers E, Meier DJ, Dumasia R, Fang J, May N, Resin Y, Armstrong DF, Saab F, Petrina M, Eagle KA, Mukherjee D: Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart 2005;91:1466-1468.
  15. Timmer JR, Hoekstra M, Nijsten MW, van der Horst IC, Ottervanger JP, Slingerland RJ, Dambrink JH, Bilo HJ, Zijlstra F, van ‘t Hof AW: Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011;124:704-711.
  16. Hoebers LP, Damman P, Claessen BE, Vis MM, Baan J Jr, van Straalen JP, Fischer J, Koch KT, Tijssen JG, de Winter RJ, Piek JJ, Henriques JP: Predictive value of plasma glucose level on admission for short and long term mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2012;109:53-59.
  17. Ishihara M, Kojima S, Sakamoto T, Kimura K, Kosuge M, Asada Y, Tei C, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Shirai M, Hiraoka H, Honda T, Ogata Y, Ogawa H, Japanese Acute Coronary Syndrome Study (JACCS) Investigators: Comparison of blood glucose values on admission for acute myocardial infarction in patients with versus without diabetes mellitus. Am J Cardiol 2009;104:769-774.
  18. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-1701.
  19. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K: Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7.
  20. Yngen M, Norhammar A, Hjemdahl P, Wallen NH: Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res 2006;3:52-56.
  21. Worthley MI, Holmes AS, Willoughby SR, Kucia AM, Heresztyn T, Stewart S, Chirkov YY, Zeitz CJ, Horowitz JD: The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 2007;49:304-310.
  22. Ceriello A: Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-1125.
  23. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM: Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011;34:1419-1423.
  24. Khoo J, Tay TL, Foo JP, Tan E, Soh SB, Chen R, Au V, Jen-Min Ng B, Cho LW: Sensitivity of A1c to diagnose diabetes is decreased in high-risk older Southeast Asians. J Diabetes Complications 2012;26:99-101.
  25. Lee JM, Wu EL, Tarini B, Herman WH, Yoon E: Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr 2011;158:947-952, e941-e943.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: May 02, 2013
Accepted: July 25, 2013
Published online: November 13, 2013
Issue release date: December 2013

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.